Morgan Stanley’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Morgan Stanley’s Portfolio EPRS Stock Details EPRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-1,074	Closed	–	–	6775
2016 Q2	$0	Buy	1,074 +841	+361%	+$1.35K	﹤0.01%	7007
2016 Q1	$1K	Buy	233 +83	+55%	+$233	﹤0.01%	6536
2015 Q4	$0	Sell	150 -1,500	-91%	-$6.76K	﹤0.01%	7121
2015 Q3	$7K	Sell	1,650 -166	-9%	-$975	﹤0.01%	6344
2015 Q2	$11K	Sell	1,816 -2,512	-58%	-$17.1K	﹤0.01%	6290
2015 Q1	$38K	Buy	4,328 +545	+14%	+$4.38K	﹤0.01%	5890
2014 Q4	$22K	Buy	3,783 +2,770	+273%	+$14.5K	﹤0.01%	6031
2014 Q3	$7K	Buy	+1,013	New	+$8.76K	﹤0.01%	6288

Other funds holding EPRS

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Morgan Stanley's EPRS Position: Q3 2016 in Review

Morgan Stanley sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q3 2016, closing a stake of 1,074 shares.

Morgan Stanley first reported a position in EPRS in Q3 2014 and held it in 8 quarters. The position peaked at $38K in Q1 2015. 3 funds tracked by Wall St. Rank hold EPRS as of Q3 2016.

Morgan Stanley reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q3 2016 after selling out during the quarter.
Morgan Stanley sold 1,074 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q3 2016.
Morgan Stanley first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q3 2014 and held it in 8 quarters.
Morgan Stanley's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $38K in Q1 2015.
3 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q3 2016.

Based on Morgan Stanley's 13F filing for Q3 2016, filed 10 Nov 2016.